Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance

Zhe-Yu Hu,Ning Xie,Can Tian, Xiaohong Yang,Liping Liu,Jing Li,Huawu Xiao, Hui Wu,Jun Lu,Jianxiang Gao,Xuming Hu, Min Cao,Zhengrong Shui,Mengjia Xiao,Yu Tang,Qiongzhi He,Lianpeng Chang,Xuefeng Xia,Xin Yi,Qianjin Liao

EBioMedicine（2018）

引用 0|浏览0

暂无评分

摘要

•Doctors felt difficult to design effective regimen for MBC patients after multi-line treatment.•ctDNA testing provide potential treatment targets and reflect treatment response of tumors.•ctDNA gene mutation pattern varies among four HR/HER2 subgroups.•The gene mutation patterns also varied between resistant patients and sensitive patients.•In COX model, ctDNA gene mutation pattern could successfully predict progression within 6 months.

查看译文

关键词

Circulating tumor DNA (ctDNA),Drug resistance,Gene mutation pattern,HR/HER2 subtype,Metastatic breast cancer,Progression-free survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要